Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2005-05-17
2005-05-17
Paras, Peter (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S013000
Reexamination Certificate
active
06894205
ABSTRACT:
Provided are in vivo screening methods to detect and identify substances that affect neuronal viability, and/or prevent neurodegeneration, and/or confer neuroprotective effects. The screening methods utilize recombinantC. elegansexpressing a detectable marker in neuronal sub-groups and the use of neurotoxins specific to specific neuronal cells. Also provided are methods for identifying modulators of neurotransmitter transporters such as the dopamine transporter. Therefore, the invention provides methods for identifying substances that can be used in the prevention and therapy of neurodegenerative diseases.
REFERENCES:
Baffi et al., “Differential expression of tyrosine hydroxylase in catecholaminergic neurons of neonatal wild-type and Nurr1-deficient mice,”Neuroscience, 93(2):631-642, 1999.
Barker and Blakely, “Norepinephrine and Serotonin transporters. Molecular targets of antidepressant drugs,” InPsychopharmoacology: The Fourth Generation of Progress(Ed. By Bloom and Kupfer), Chapter 28: 321-333, 1995.
Braungart et al., “MPTP-based test system for Parkinson's disease C. elegans,” 2001 International Worm Meeting Abstract 128.
Chalfie et al., “Green fluorescent protein as a marker for gene expression,”Science, 263:802-805, 1994.
Choi et al., “Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK,”J. Neurosci. Res., 57:86-94, 1999.
Fradkov et al., “A novel fluorescent protein from Discosoma coral and its mutants possesses a unique far-red fluorescence,”FEBS Lett, 479:127-130, 2000.
Heim et al., “Wavelength mutations and posttranslational autoxidation of green fluorescent protein,”Proc. Natl. Acad. Sci., USA, 91:12501-12504, 1994.
Jayanthi et al., “The Caenorhabditis elegans gene T23G5.5 encodes and antidepressant- and cocaine-sensitive dopamine transporter,”Mol. Pharmacology, 54:601-609, 1998.
Kitayama et al., “Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA,”Ann. Neurol., 32(1):109-111, 1992.
Koelle et al., “C. elegans gene knockout protocol,” Article found at http://info.med.yale.edu/mbb/koelle/protocols_Gene_knockouts.html. Updated Sep. 18, 2000.
Link et al., “A transgenic C. elegans model for Parkinson's disease,” 2001 International Worm Meeting Abstract 879.
Lotharius et al., “Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons,”J. Neuroscience, 19(4):1284-1293, 1999.
Miller et al., “Two-color GFP expression for C. elegans,”Biotechniques, 26:914-921, 1999.
Miller et al., “Dopamine transporters and neuronal injury,”Trends Pharm. Sci., 20:424-429, 1999.
Nass et al., “Neurotoxin-induced degenration of dopamine neurons in Caenorhabditis elegans,”PNAS, 99(5):3264-3269, 2002.
Blakely Randy D.
Miller David
Nass Richard
Fulbright & Jaworski LLP
Paras Peter
Vanderbilt University
LandOfFree
Assay for toxin induced neuronal degeneration and viability... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay for toxin induced neuronal degeneration and viability..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay for toxin induced neuronal degeneration and viability... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374991